secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-197489
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia raises ~$194.6M in public offering of 16.7M shares at $10.75; preliminary cash $517.2M as of March 31
--------------------------------------------------------------------------------

- Offered 16,744,187 shares at $10.75/share; underwriters exercised full option for 2,511,628 additional shares; net proceeds ~$194.6M.
- Proceeds will advance clinical development and commercial launch prep for lonvoguran ziclumeran (HAE), pipeline R&D, and potential acquisitions.
- Preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026: ~$517.2M; raised $33.6M from ATM program in Q1.
- Company expects combined cash to fund expenses into 2028, excluding potential HAE product revenue, milestone payments, or strategic capital.
- Potential FDA approval of lonvoguran ziclumeran for hereditary angioedema anticipated in first half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/0001193125-26-197489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/d308328d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-197489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer